JP6174997B2 - ホスホジエステラーゼ阻害剤としてのベンゾジオキソールまたはベンゾジオキセピンヘテロ環化合物 - Google Patents

ホスホジエステラーゼ阻害剤としてのベンゾジオキソールまたはベンゾジオキセピンヘテロ環化合物 Download PDF

Info

Publication number
JP6174997B2
JP6174997B2 JP2013515698A JP2013515698A JP6174997B2 JP 6174997 B2 JP6174997 B2 JP 6174997B2 JP 2013515698 A JP2013515698 A JP 2013515698A JP 2013515698 A JP2013515698 A JP 2013515698A JP 6174997 B2 JP6174997 B2 JP 6174997B2
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
spiro
difluoromethoxy
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013515698A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013529602A (ja
JP2013529602A5 (cg-RX-API-DMAC7.html
Inventor
シモン・フェルベク・ニールセン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leo Pharma AS
Original Assignee
Leo Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma AS filed Critical Leo Pharma AS
Publication of JP2013529602A publication Critical patent/JP2013529602A/ja
Publication of JP2013529602A5 publication Critical patent/JP2013529602A5/ja
Application granted granted Critical
Publication of JP6174997B2 publication Critical patent/JP6174997B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
JP2013515698A 2010-06-24 2011-06-24 ホスホジエステラーゼ阻害剤としてのベンゾジオキソールまたはベンゾジオキセピンヘテロ環化合物 Active JP6174997B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35820910P 2010-06-24 2010-06-24
US61/358,209 2010-06-24
PCT/DK2011/000069 WO2011160632A1 (en) 2010-06-24 2011-06-24 Benzodioxole or benzodioxepine heterocyclic compounds phosphodiesterase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016052707A Division JP2016164168A (ja) 2010-06-24 2016-03-16 ホスホジエステラーゼ阻害剤としてのベンゾジオキソールまたはベンゾジオキセピンヘテロ環化合物

Publications (3)

Publication Number Publication Date
JP2013529602A JP2013529602A (ja) 2013-07-22
JP2013529602A5 JP2013529602A5 (cg-RX-API-DMAC7.html) 2014-07-03
JP6174997B2 true JP6174997B2 (ja) 2017-08-02

Family

ID=44351701

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013515698A Active JP6174997B2 (ja) 2010-06-24 2011-06-24 ホスホジエステラーゼ阻害剤としてのベンゾジオキソールまたはベンゾジオキセピンヘテロ環化合物
JP2016052707A Pending JP2016164168A (ja) 2010-06-24 2016-03-16 ホスホジエステラーゼ阻害剤としてのベンゾジオキソールまたはベンゾジオキセピンヘテロ環化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016052707A Pending JP2016164168A (ja) 2010-06-24 2016-03-16 ホスホジエステラーゼ阻害剤としてのベンゾジオキソールまたはベンゾジオキセピンヘテロ環化合物

Country Status (29)

Country Link
US (3) US8980905B2 (cg-RX-API-DMAC7.html)
EP (2) EP2585469B1 (cg-RX-API-DMAC7.html)
JP (2) JP6174997B2 (cg-RX-API-DMAC7.html)
KR (1) KR101864578B1 (cg-RX-API-DMAC7.html)
CN (1) CN102958937B (cg-RX-API-DMAC7.html)
AU (1) AU2011269429B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012032813B1 (cg-RX-API-DMAC7.html)
CA (1) CA2802895C (cg-RX-API-DMAC7.html)
CY (2) CY1117862T1 (cg-RX-API-DMAC7.html)
DK (2) DK3070091T3 (cg-RX-API-DMAC7.html)
ES (2) ES2584055T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20160919T1 (cg-RX-API-DMAC7.html)
HU (2) HUE030081T2 (cg-RX-API-DMAC7.html)
IL (1) IL223329A (cg-RX-API-DMAC7.html)
LT (2) LT3070091T (cg-RX-API-DMAC7.html)
MX (1) MX2012014131A (cg-RX-API-DMAC7.html)
MY (1) MY157481A (cg-RX-API-DMAC7.html)
NZ (1) NZ603895A (cg-RX-API-DMAC7.html)
PL (2) PL2585469T3 (cg-RX-API-DMAC7.html)
PT (2) PT2585469T (cg-RX-API-DMAC7.html)
RS (2) RS55104B1 (cg-RX-API-DMAC7.html)
RU (1) RU2583787C2 (cg-RX-API-DMAC7.html)
SG (1) SG186140A1 (cg-RX-API-DMAC7.html)
SI (2) SI2585469T1 (cg-RX-API-DMAC7.html)
TR (1) TR201909709T4 (cg-RX-API-DMAC7.html)
TW (1) TWI507410B (cg-RX-API-DMAC7.html)
UA (1) UA109140C2 (cg-RX-API-DMAC7.html)
WO (1) WO2011160632A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201209031B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014083099A1 (en) * 2012-11-30 2014-06-05 Leo Pharma A/S A method of inhibiting the expression of il-22 in activated t-cells
PL3157930T3 (pl) * 2014-06-23 2019-04-30 Leo Pharma As Sposoby wytwarzania związków heterocyklicznych 1,3-benzodioksolu
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
PT3390407T (pt) * 2015-12-18 2023-11-03 Union Therapeutics As Métodos para a preparação de compostos heterocíclicos de 1,3-benzodioxole
MX394835B (es) 2017-06-20 2025-03-24 Union Therapeutics As Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
PT3724196T (pt) 2017-12-15 2023-01-13 Union Therapeutics As Azetidina di-hidrotienopiridinas substituídas e a sua utilização como inibidores de fosfodiesterase
CN120097995A (zh) 2018-05-21 2025-06-06 星座制药公司 甲基修饰酶的调节剂、其组合物和用途
EA202191955A1 (ru) * 2019-01-15 2021-10-07 Юнион Терапьютикс А/С Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы
JP7530420B2 (ja) * 2019-07-24 2024-08-07 コンステレーション・ファーマシューティカルズ・インコーポレイテッド がんの治療のためのｅｚｈ２阻害併用療法
CN112552276B (zh) * 2019-09-25 2023-03-21 中国科学院上海药物研究所 苯并氧杂卓-5-酮类化合物及其制备方法和用途
EP4313043A1 (en) 2021-03-22 2024-02-07 UNION therapeutics A/S Treatment of hidradenitis suppurativa with orismilast
GB202205715D0 (en) 2022-04-19 2022-06-01 Union Therapeutics As Treatment of neutrophilic dermatoses
GB202306662D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Dosage regimen
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ290266B6 (cs) * 1993-07-02 2002-06-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituované benzamidy, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
GB9507297D0 (en) 1995-04-07 1995-05-31 Rh Ne Poulenc Rorer Limited New composition of matter
DK0771794T3 (da) 1995-05-19 2006-09-11 Kyowa Hakko Kogyo Kk Oxygenholdige heterocykliske forbindelser
NZ332340A (en) * 1996-05-20 2000-04-28 Darwin Discovery Ltd 4-(aryl or heteroaryl) substituted benzofurancarboxamide derivatives and medicaments
CA2272327A1 (en) 1996-11-19 1998-05-28 Kyowa Hakko Kogyo Co., Ltd. Oxygen-containing heterocyclic compounds
JP2005060375A (ja) * 2003-07-28 2005-03-10 Kyowa Hakko Kogyo Co Ltd 含酸素複素環化合物
DE10360792A1 (de) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
AU2005315319B2 (en) * 2004-12-17 2011-07-07 Glenmark Pharmaceuticals S.A. Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders
UA98639C2 (en) * 2007-02-28 2012-06-11 Лео Фарма А/С Phosphodiesterase inhibitors
MX2009009238A (es) * 2007-02-28 2009-09-08 Leo Pharma As Nuevos inhibidores de fosfodiesterasa.
EP2794603B1 (en) * 2011-12-21 2016-06-15 Leo Pharma A/S [1,2,4]triazolopyridines and their use as phospodiesterase inhibitors

Also Published As

Publication number Publication date
US9637499B2 (en) 2017-05-02
CY1117862T1 (el) 2017-05-17
BR112012032813B1 (pt) 2022-02-01
PT3070091T (pt) 2019-07-22
PL3070091T3 (pl) 2019-09-30
JP2016164168A (ja) 2016-09-08
KR101864578B1 (ko) 2018-06-07
SI2585469T1 (sl) 2016-11-30
ES2584055T3 (es) 2016-09-23
SI3070091T1 (sl) 2019-08-30
SG186140A1 (en) 2013-01-30
JP2013529602A (ja) 2013-07-22
IL223329A (en) 2017-01-31
TW201206940A (en) 2012-02-16
IL223329A0 (en) 2013-02-03
AU2011269429A1 (en) 2012-12-20
CN102958937A (zh) 2013-03-06
EP3070091A1 (en) 2016-09-21
UA109140C2 (uk) 2015-07-27
NZ603895A (en) 2014-10-31
HUE044301T2 (hu) 2019-10-28
TWI507410B (zh) 2015-11-11
MY157481A (en) 2016-06-15
PT2585469T (pt) 2016-08-29
LT2585469T (lt) 2016-10-10
RS58945B1 (sr) 2019-08-30
US8980905B2 (en) 2015-03-17
HRP20160919T1 (hr) 2016-10-07
CA2802895C (en) 2019-05-21
DK2585469T3 (en) 2016-08-29
AU2011269429B2 (en) 2015-07-09
HRP20191136T1 (hr) 2019-09-20
RU2583787C2 (ru) 2016-05-10
HK1182699A1 (zh) 2013-12-06
RU2013103079A (ru) 2014-07-27
DK3070091T3 (da) 2019-07-08
TR201909709T4 (tr) 2019-07-22
RS55104B1 (sr) 2016-12-30
MX2012014131A (es) 2013-01-29
US20150111915A1 (en) 2015-04-23
HUE030081T2 (en) 2017-04-28
ES2733092T3 (es) 2019-11-27
US20130123291A1 (en) 2013-05-16
CN102958937B (zh) 2016-03-30
EP2585469B1 (en) 2016-05-25
CA2802895A1 (en) 2011-12-29
WO2011160632A1 (en) 2011-12-29
US20160022657A1 (en) 2016-01-28
LT3070091T (lt) 2019-07-25
ZA201209031B (en) 2014-02-26
US9273064B2 (en) 2016-03-01
PL2585469T3 (pl) 2017-07-31
EP3070091B1 (en) 2019-04-17
EP2585469A1 (en) 2013-05-01
BR112012032813A2 (pt) 2016-11-08
KR20130038341A (ko) 2013-04-17
CY1122201T1 (el) 2020-11-25

Similar Documents

Publication Publication Date Title
JP6174997B2 (ja) ホスホジエステラーゼ阻害剤としてのベンゾジオキソールまたはベンゾジオキセピンヘテロ環化合物
US8338431B2 (en) Phosphodiesterase inhibitors
HK1182699B (en) Benzodioxole or benzodioxepine heterocyclic compounds phosphodiesterase inhibitors
TWI432439B (zh) 新穎磷酸二酯酶抑制劑
NZ625849B2 (en) [1,2,4]triazolopyridines and their use as phosphodiesterase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140508

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140508

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150310

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150609

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170417

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170707

R150 Certificate of patent or registration of utility model

Ref document number: 6174997

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250